Business Development

Business Development

Researchers in the National Drug Discovery Centre
WEHI has a strong track record in early capture of intellectual property and commercialisation. 

Through our established partnerships with pharmaceutical or biotech companies we are developing novel therapies that could be effective in treating certain cancers, immune disorders and infectious diseases as well as developmental and neurodegenerative diseases.

Partnerships and collaborations

Microscopic image of cells

Developing new cancer immunotherapies

Illustration of dying cell

Targeting MCL-1, cancer’s Achilles heel

Microscopic image of cells

Necroptosis research leads to spin-out company

 

Outcomes

  • 30 projects commercialised by WEHI and under development with partners
  • 18 proprietary projects under discussions with potential industry partners and investors
  • Active management of 11 strategic alliances
  • Development and management of more than 500 agreements executed every year with local and international partners
  • 45 WEHI-originated patent families actively maintained; 17 patents successfully licensed to third parties

Partnered projects

Licensing and co-development partnerships

WEHI research teams focus on solving complex biological questions and linking laboratory results to clinical outcomes. The Business Development Office is always seeking partnerships to push our drug discovery and development programs forward.

Current partnering opportunities

Start-up companies

The Business Development Office also supports the development of start-up companies created based on intellectual property developed within WEHI.

WEHI’s start-up companies 

Business Development Office

The Business Development team is comprised of highly qualified professionals with expertise in biomedical science, biotech and industry research and development, business development, intellectual property management and commercialisation. 

How we work

Venetoclax timeline of discovery

Starting with a landmark discovery in 1988, follow the story of how Institute research has driven development of a breakthrough anti-cancer drug.